search

Active clinical trials for "Immunoglobulin G4-Related Disease"

Results 11-20 of 34

Study of Sirolimus in IgG4-related Disease

IgG4-related Disease

gG4-related disease (IgG4-RD) is a newly recognized systemic autoimmune disease that can involve the pan-creatobiliary tract, retroperitoneum/aorta, head and neck region, and salivary glands, et al. Glucocorticoids are the first-line agents for the treatment of IgG4-RD, however, in order to maintain long-term disease stability and avoid disease relapse, glucocorticoids maintenance therapy should last for a long period, which may induce various glucocorticoid-associated adverse reactions. Sirolimus plays dual roles in inhibiting lymphocyte activation and fibroblast proliferation. It is inferred from its mechanism that sirolimus is a good potential treatment option for IgG4-RD. Therefore, we conducted this single-arm clinical trial on patients with IgG4-RD to determine the efficacy and safety of sirolimus.

Not yet recruiting3 enrollment criteria

Immunoglobulin G4 and Immunoglobulin E Antibodies in a Population With Adverse Reactions to Foodstuffs-related...

Immunoglobulin E-Mediated Food AllergyImmunoglobulin G4-Related Disease2 more

The aim of this study is to analyze a population with symptoms associated with adverse reactions to foodstuffs (ARFS). To determine the levels of food-specific immunoglobulin G4 (IgG4) and immunoglobulin E (IgE) antibody reactions (AbR).

Recruiting3 enrollment criteria

Study to Evaluate the Efficacy and Safety of CM310 in Subjects With IgG4-related Disease

IgG4 Related Disease

This study is a single-arm study initiated to evaluate the efficacy and safety of CM310 in subjects with recurrent IgG4-related disease.

Not yet recruiting7 enrollment criteria

National Registry of IgG4-RD in China

IgG4-Related Disease

The aim of this study is to establish a nation-wide cohort study of IgG4-related disease (IgG4-RD) in China. Methods: All the patients fulfilling diagnostic criteria of IgG4-RD (2011) would be enrolled from multi-centers around China. A online database system has been established. Endpoints: The primary endpoint is to investigate the clinical manifestations of Chinese IgG4-RD patients; the secondary endpoints including the demographic features,laboratory characteristics, immunological tests, imaging and pathological features, in addition, the treatment and prognosis of the disease.

Recruiting2 enrollment criteria

Meir Medical Center Rheumatologic Biobank

Rheumatoid ArthritisLupus Erythematosus4 more

Serum, synovial fluid and skin biopsies from patients will be collected to the biobank with rheumatoid diseases. These samples will later be used for clinical and basic research, following approval of each specific study by the IRB. The investigators intend to extract protein, DNA and RNA from each sample.

Recruiting4 enrollment criteria

A Prospective Cohort Study of IgG4RD in China

IgG4-related Disease

This is an cohort study to investigate the disease course and treatment response of patients with IgG4-related disease.

Recruiting10 enrollment criteria

Safety and Efficacy of Abatacept in IgG4-Related Disease

IgG4-related Disease

This is a Phase 2, single center, proof of concept clinical trial in subjects with active IgG4-Related Disease (IgG4-RD). Approximately 10 subjects with active IgG4-RD will be enrolled into this study. Subjects will receive weekly subcutaneous doses of abatacept (125mg) for 24 doses (24 weeks).

Completed33 enrollment criteria

Study to Evaluate the Effect of XmAb®5871 on Disease Activity in Patients With IgG4-Related Disease...

IgG4-RD

The purpose of this Phase 2 study is to investigate the effect of XmAb5871 on IgG4-Related Disease (RD) activity

Completed17 enrollment criteria

Leflunomide for Maintenance of Remission in IgG4 Related Disease

Immunoglobulin G4 Related Sclerosing Disease

The study has been designed as a 12-month, open-label, randomized, controlled study comparing the use of prednisone mono-therapy and prednisone and leflunomide combination therapy in treating patients with IgG4-related disease.

Completed18 enrollment criteria

Treatment of IgG4-Related Disease With Revlimid and Rituximab

Immunoglobulin G Subclass 4 Related DiseaseIgG4-related Disease3 more

Among persons with Immunoglobulin G subclass 4 Related Disease (IgG4)-related disease who have persistent or recurrent disease despite standard therapies, does combination therapy with rituximab and revlimid cause a sustained disease remission?

Completed26 enrollment criteria

Need Help? Contact our team!


We'll reach out to this number within 24 hrs